Drugs / PIT565
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07029555 | Jun 2025 → May 2028 expected | rheumatoid arthritis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06335979 | Oct 2024 → Nov 2027 expected | systemic lupus erythematosus | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05397496 | Oct 2022 → Aug 2026 overdue | B-cell acute lymphoblastic leukemia | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PIT565 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05397496 ↗ |
| Route | Intravenous | “Intravenous (i.v.) infusion” NCT05397496 ↗ |